Subha Mukherjee

Subha Mukherjee

Auto-generated profile, based on publicly available information

Subha Mukherjee

Chemical Process Development, Bristol Myers Squibb, New Brunswick, New Jersey 08903, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2019 in The Journal of Organic Chemistry
Verified
Journal Article
Open access
AIAlbert Isidro-Llobet
Albert Isidro-Llobet
MKMartin N. Kenworthy
Martin N. Kenworthy
SMSubha Mukherjee
Subha Mukherjee
MKMichael E. Kopach
Michael E. Kopach
KWKatarzyna Wegner
Katarzyna Wegner
FRFrank Roschangar
Frank Roschangar
In recent years, there has been a growing interest in therapeutic peptides within the pharmaceutical industry with more than 50 peptide drugs on the market, approximately 170 in clinical trials, and >200 in preclinical development. However, the current state of the art in peptide synthesis involves primarily legacy technologies with use of large amounts of highly hazardous reagents and solvents and little focus on green chemistry and engineering. In 2016, the ACS Green Chemistry Institute Pharmaceutical Roundtable identified development of greener processes for peptide API as a critical unmet need, and as a result, a new Roundtable team formed to address this important area. The initial focus of this new team is to highlight best practices in peptide synthesis and encourage much needed innovations. In this Perspective, we aim to summarize the current challenges of peptide synthesis and purification in terms of sustainability, highlight possible solutions, and encourage synergies between academia, the pharmaceutical industry, and contract research organizations/contract manufacturing organizations.

20 March 2024 in The Journal of Organic Chemistry
Verified
Journal Article
Open access
IKIvy Kekessie
Ivy Kekessie
KWKatarzyna Wegner
Katarzyna Wegner
IMIsamir Martinez
Isamir Martinez
MKMichael E. Kopach
Michael E. Kopach
TWTimothy D. White
Timothy D. White
LBLeendert J. van Den Bos
Leendert J. van Den Bos
Small molecule therapeutics represent the majority of the FDA-approved drugs. Yet, many attractive targets are poorly tractable by small molecules, generating a need for new therapeutic modalities. Due to their biocompatibility profile and structural versatility, peptide-based therapeutics are a possible solution. Additionally, in the past two decades, advances in peptide design, delivery, formulation, and devices have occurred, making therapeutic peptides an attractive modality. However, peptide manufacturing is often limited to solid-phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and to a lesser extent hybrid SPPS/LPPS, with SPPS emerging as a predominant platform technology for peptide synthesis. SPPS involves the use of excess solvents and reagents which negatively impact the environment, thus highlighting the need for newer technologies to reduce the environmental footprint. Herein, fourteen American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR) member companies with peptide-based therapeutics in their portfolio have compiled Process Mass Intensity (PMI) metrics to help inform the sustainability efforts in peptide synthesis. This includes PMI assessment on 40 synthetic peptide processes at various development stages in pharma, classified according to the development phase. This is the most comprehensive assessment of synthetic peptide environmental metrics to date. The synthetic peptide manufacturing process was divided into stages (synthesis, purification, isolation) to determine their respective PMI. On average, solid-phase peptide synthesis (SPPS) (PMI ≈ 13,000) does not compare favorably with other modalities such as small molecules (PMI median 168-308) and biopharmaceuticals (PMI ≈ 8300). Thus, the high PMI for peptide synthesis warrants more environmentally friendly processes in peptide manufacturing.

15 March 2024 in Organic Process Research & Development
Verified
Journal Article
Closed access
RFRichard J. Fox
Richard J. Fox
JBJ. Daniel Bailey
J. Daniel Bailey
JOJennifer Victoriano Obligacion
Jennifer Victoriano Obligacion
NBNiginia Borlinghaus
Niginia Borlinghaus
WBWilfried M. Braje
Wilfried M. Braje
SVStella Vukelić
Stella Vukelić

25 April 2024 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
SMSubha Mukherjee
Subha Mukherjee
ARAmanda Rogers
Amanda Rogers
GCGardner Creech
Gardner Creech
CHChao Hang
Chao Hang
ARAntonio Ramirez
Antonio Ramirez
CSChris Sfouggatakis
Chris Sfouggatakis

26 February 2025 in Organic Process Research & Development
Verified
Journal Article
Closed access
SMSubha Mukherjee
Subha Mukherjee
DTDavid A. Thaisrivongs
David A. Thaisrivongs
PAParidhi Agrawal
Paridhi Agrawal
MBMark R. Berglund
Mark R. Berglund
AFAlec Fettes
Alec Fettes
KSKevin D. Seibert
Kevin D. Seibert

23 April 2024 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
JKJames Kempson
James Kempson
RZRulin Zhao
Rulin Zhao
JPJoseph Pawluczyk
Joseph Pawluczyk
BWBei Wang
Bei Wang
HZHuiping Zhang
Huiping Zhang
AMArvind Mathur
Arvind Mathur